Neuroprotective Agents Should NOT Be Used in Acute Intracerebral Hemorrhage with Uncal Herniation
Do not use citicoline, edaravone, or cerebrolysin in this patient—none of these agents have demonstrated mortality or functional outcome benefit in intracerebral hemorrhage, and your immediate priority must be life-saving interventions for herniation.
Why Neuroprotective Agents Are Not Recommended
The most authoritative guidance comes from the 2022 AHA/ASA ICH Guidelines 1 and 2015 AHA/ASA ICH Guidelines 2, which do not recommend any neuroprotective agents for ICH. This is reinforced by the 2013 AHA/ASA Ischemic Stroke Guidelines 3, which explicitly state: "No medication with putative neuroprotective effects has yet been shown to be useful for treatment of patients with acute ischemic stroke" 4—and the evidence is even weaker for hemorrhagic stroke.
Specific Agent Analysis:
Citicoline:
- The large ICTUS trial (2298 patients) was stopped prematurely in 2011 for futility with no difference in 90-day outcomes (OR 1.03,95% CI 0.86-1.25, P=0.364) 3
- This was for ischemic stroke—there is no evidence supporting its use in ICH
- Multiple prior trials and meta-analyses failed to demonstrate benefit 3
Edaravone:
- FDA-approved ONLY for ALS, not stroke 5
- A 2011 Cochrane review of edaravone in ICH found all 10 trials were of poor quality, showed no reduction in death or dependency, and concluded "further high quality, large scale RCTs are required" 6
- While it showed transient improvement in neurological impairment scores during treatment, this did not translate to any longer-term clinical benefit 6
- The 2020 protocol update 7 confirms ongoing uncertainty about efficacy and safety
Cerebrolysin:
- No high-quality evidence supports its use in ICH
- A 2025 study 8 in traumatic brain injury (not ICH) showed only a "tendency toward better outcomes" without statistical significance
- Not mentioned in any major stroke guidelines
What You SHOULD Be Doing Instead
For a patient with ICH causing uncal herniation, the 2025 HEADS Roundtable 9 and 2022 AHA/ASA Guidelines 1 emphasize that "every minute counts" and immediate interventions targeting mass effect are critical:
Immediate Life-Saving Measures:
- Hyperosmolar therapy (mannitol) for elevated ICP 10, 1
- Emergency ventricular drainage if hydrocephalus present 1, 11
- Decompressive craniotomy as a life-saving measure for deteriorating patients with herniation 1
- Blood pressure control to systolic <140 mmHg to prevent hematoma expansion 9, 12
- Reversal of coagulopathy if present 2, 12
Critical Timing Considerations:
The 2025 HEADS consensus 9 emphasizes that interventions are most effective within the first hours after ICH onset. The pathophysiology involves:
- Primary injury from hematoma expansion (greatest in first few hours)
- Secondary injury from hemolysis and neuroinflammation (hours to weeks)
The neutral results of neuroprotectant trials may reflect delayed treatment initiation 9, but even early administration has failed to show benefit.
Common Pitfalls to Avoid:
- Therapeutic nihilism: Don't give up on aggressive supportive care 11
- Delayed prognostication: Avoid early pessimistic predictions in the first few days 11
- Wasting time on unproven therapies: Focus on evidence-based interventions that target mass effect and prevent hematoma expansion 9, 13, 11
The Bottom Line:
In a patient with uncal herniation from ICH, neuroprotective agents have no role. Your focus must be on immediate surgical and medical interventions to reduce intracranial pressure and prevent death. The 2022 guidelines 1 and recent evidence 9, 11, 12 support aggressive bundled care within 60 minutes ("Code ICH"), but this bundle does not include any neuroprotective medications.